Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 5/20 | 0.41 |
| ▸ | CDK9 | P50750 | 5/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14287305 | 0.85 | CCNT1 (0.44) | CCNT1CDK9SCN9ALRRK2PTGDR2 | |
| SCHEMBL14287067 | 0.83 | MKNK1 (0.40) | MKNK1MAOBHTR6MAOASLC6A4 | |
| SCHEMBL5095974 | 0.81 | CCNT1 (0.39) | CCNT1CDK9SCN9ALRRK2MKNK1 | |
| SCHEMBL4356513 | 0.81 | RAB9A (0.46) | CCNT1CDK9SCN9APTGDR2 | |
| SCHEMBL14287065 | 0.80 | MKNK1 (0.47) | MKNK1MAOBHTR6MAOASLC6A4 | |
| SCHEMBL6611465 | 0.78 | HDAC1 (0.38) | — | |
| SCHEMBL14287271 | 0.77 | CCNT1 (0.36) | CCNT1CDK9SCN9ALRRK2MKNK1 | |
| SCHEMBL14287250 | 0.77 | CCNT1 (0.36) | CCNT1CDK9SCN9ALRRK2MKNK1 | |
| SCHEMBL17197369 | 0.77 | DRD1 (0.45) | MAOBMAOASLC6A4 | |
| SCHEMBL4363792 | 0.74 | KDM4E (0.39) | CCNT1CDK9SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| WO-2008144931-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008144931-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-04 | — | — | WO | disclosed |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | CCNT1 4868/4885CDK9 4231/4885SCN9A 126/4885 |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | ASIC1, ASIC3, TRPV1 | CCNT1 4864/4885CDK9 4007/4885SCN9A 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.